Core Insights - The company reported a total revenue of 1.889 billion yuan for Q3 2025, a decrease of 19.2682 million yuan compared to the same period last year, representing a year-on-year decline of 1.01% [1] - The net profit attributable to shareholders was 251 million yuan, while the net cash inflow from operating activities was 155 million yuan, ranking 38th among disclosed peers, and decreased by 145 million yuan year-on-year, a decline of 48.42% [1] Financial Metrics - The latest debt-to-asset ratio stands at 20.16% [3] - The latest gross profit margin is 56.80%, down by 1.27 percentage points from the previous quarter [3] - The return on equity (ROE) is reported at 6.22% [3] - The diluted earnings per share (EPS) is 0.30 yuan [3] - The total asset turnover ratio is 0.35 times, and the inventory turnover ratio is 2.06 times [3] Shareholder Information - The number of shareholders is 72,900, with the top ten shareholders holding a total of 282 million shares, accounting for 33.24% of the total share capital [3] - The top shareholders include: - Zhang Yuchong: 10.91% - Zhang Yuli: 10.91% - Hong Kong Central Clearing Limited: 2.66% - Industrial Bank Co., Ltd. - Xingquan Trend Investment Mixed Securities Investment Fund: 1.94% - Chen Yonghong: 1.61% - China Merchants Bank Co., Ltd. - Xingquan He Run Mixed Securities Investment Fund: 1.28% - China Construction Bank Co., Ltd. - Xingquan Multi-Dimensional Value Mixed Securities Investment Fund: 1.13% - National Social Security Fund 604 Portfolio: 0.95% - Li Yujian: 0.94% - Bank of China Co., Ltd. - Xingquan He Feng Three-Year Holding Period Mixed Securities Investment Fund: 0.91% [3]
众生药业(002317.SZ):2025年三季报净利润为2.51亿元